Hepatitis C Stocks List

Hepatitis C Stocks Recent News

Date Stock Title
May 15 ABBV AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript
May 15 INO Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
May 15 VRTX Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
May 15 VRTX Jennifer Schneider Elected to Vertex Board of Directors
May 15 NNVC NanoViricides GAAP EPS of -$0.16
May 15 NNVC NanoViricides Has Filed its Quarterly Report
May 15 ABBV NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
May 15 UTHR Q1 2024 Liquidia Corp Earnings Call
May 14 INO Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
May 14 VRTX Vertex Stock Hit All-Time High, Paused, Rising Again
May 14 UTHR Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
May 14 ABBV AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
May 14 VRTX Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
May 14 NNVC A Novel Broad-Spectrum Antiviral with Activity Against RSV
May 14 ABBV 3 Magnificent Stocks That Are Passive Income Machines
May 14 INO Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 14 INO Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
May 13 INO Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
May 13 INO Inovio Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 13 INO Inovio Pharmaceuticals GAAP EPS of -$1.31 misses by $0.31
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags